GlassScriptPhysician profile
Coleen R Davis
NPI 1932342433
$3,525.01
in general payments reported to CMS, 2019-2025
28 companies · $674 in 2025
The $674 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $142 · 2021: $674 · 2022: $592 · 2023: $770 · 2024: $672 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,116.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $584.34 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $479.59 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $381.79 | 2020-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $328.24 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $190.91 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.73 | 2021-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $153.63 | 2022-2025 | Caplyta |
| Amgen INC. | $151.82 | 2020-2025 | Repatha, Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $112.09 | 2024-2025 | Eliquis, Cobenfy |
| Dexcom, INC. | $105.20 | 2023-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $88.78 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $78.60 | 2021-2023 | Xarelto |
| Exact Sciences Corporation | $76.48 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $74.08 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $72.13 | 2020-2023 | Steglatro, Belsomra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $70.03 | 2021-2025 | |
| Abbott Laboratories | $60.42 | 2022 | |
| Astellas Pharma US INC | $54.12 | 2022-2024 | Veozah |
| Endogastric Solutions, INC | $39.89 | 2023 | Esophyx |
| Hologic Sales and Service, LLC | $39.70 | 2022-2023 | Third Wave, Aptima, Thinprep 2000 Processor |
| Vanda Pharmaceuticals INC. | $37.25 | 2024 | Fanapt, Hetlioz |
| Boston Scientific Corporation | $34.73 | 2021-2025 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $32.17 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.17 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $22.06 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.38 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.76 | 2021 | |
| Electromed, INC. | $13.92 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Coleen Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.